16
Management
Table 5. Characteristics of Common Lipid-Lowering
Medications to Treat Dyslipidemia*
Class Mechanism of Action Medications
Typical Dose
Range
LDL-C–Lowering Medications (cont'd)
PCSK9
inhibitor:
small interfering
RNA
Utilizes endogenous RNA
interference mechanism and
directs catalytic breakdown
of mRNA for PCSK9 and
decreases degradation of the
LDL receptor
Inclisiran 284 mg
Bile acid
sequestrants
Bind bile acids in the gut,
interrupt enterohepatic
recirculation of bile
acids and impede their
reabsorption, decrease bile
acid pooling in the liver,
increase conversion of
cholesterol to bile acids;
increase LDL receptor
expression on the surface
of hepatocytes
Cholestyramine 8–16 g
Colesevelam 3.75 mg
Colestipol 2–16 g
LDL-C–Lowering Medications Approved Only in HoFH
Microsomal TG
transfer protein
inhibitor
Binds and inhibits
microsomal TG transfer
protein, which is essential
for the assembly of apoB-
containing lipoproteins,
and inhibiting synthesis of
chylomicrons and VLDL,
which lowers LDL-C
Lomitapide 5–60 mg
ANGPTL3
inhibitor
Fully human mAb that
binds to and inhibits
ANGPTL3; ANGPTL3
inhibition enhances remnant
lipoprotein clearance,
reducing VLDL remnants
and their conversion into
LDL particles
Evinacumab-
dgnb
15 mg/kg
(cont'd)
